Business Context and Reporting Period
This Form 8-K was filed by NantKwest, Inc. on January 19, 2016, reporting events occurring on January 19 and January 20, 2016. The filing addresses a change in executive leadership under Item 5.02.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Resignation: Angela Wilson resigned as Chief Financial Officer on January 19, 2016, for personal reasons.
- Appointment: Richard J. Tajak was appointed as interim Chief Financial Officer, effective January 20, 2016.
- Compensation Structure: Mr. Tajak's services are provided under a Shared Services Agreement with NantWorks, LLC. The Company will pay NantWorks for a portion of his salary at cost (no markup) based on time devoted, plus a reasonable allocation for indirect costs.
Management Commentary and Risks
Mr. Tajak brings significant experience, having served as CFO of NantPharma, LLC (a subsidiary of NantWorks) since 2014 and previously as CFO of APP Pharmaceuticals, Inc. and Senior Vice President of Finance for Astellas Pharmaceuticals, Inc. The filing states there are no family relationships between Mr. Tajak and other directors or officers, and no transactions requiring disclosure under Item 404(a) of Regulation S-K.
Investor Verification Checklist
- Verify the terms of the Shared Services Agreement between NantKwest, Inc. and NantWorks, LLC regarding cost allocation.
- Confirm the duration of the "interim" status for the new CFO and any plans for a permanent appointment.
- Review subsequent filings for any financial impact resulting from the leadership transition.